Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I’m talking about Lilly drugs that doctors prescribe for weight loss: Mounjaro and Zepbound. They’re both based on the same molecule, but regulators approved the product for type 2 diabetes under the name […]
(Reuters) -U.S. drugmaker Amgen’s shares jumped 14% premarket on Friday as the company said it was encouraged by interim trial data on its experimental obesity drug, denting rival stocks but leaving Wall Street frustrated over a lack of details. Amgen, which is conducting mid-stage studies of its injectable drug MariTide, said, based on interim data, […]
(Reuters) – U.S. stock index futures gained on Friday, lifted by upbeat corporate updates from Apple and Amgen, while traders braced for a key jobs report for a clearer outlook on the labor market and the interest rate path. Apple jumped 5.8%, outpacing other megacap stocks in premarket trading after the iPhone maker unveiled a […]
(Bloomberg) — Amgen Inc.’s shares soared in late trading after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide. Most Read from Bloomberg “We recognize the significant interest in obesity,” Amgen CEO Robert Bradway said Thursday on a call with investors. “We […]
Amgen (AMGN) stock surged late Thursday on its first-quarter profit beat as investors zero in on its potential rivals to Eli Lilly‘s (LLY) and Novo Nordisk‘s (NVO) obesity treatments.
Amgen (AMGN) is among several big pharmaceutical players looking for a way into the newly profitable GLP-1 obesity drug market. Chief financial officer Peter Griffith told Yahoo Finance the company is focused on creating an entire pipeline around what is estimated to be up to a $150 billion market. “When we look at the market, […]
Amgen (AMGN) stock dipped late Tuesday after the biotech company beat Wall Street’s fourth-quarter estimates, but its profit guidance for 2024 came up short. X For the year, the biotech giant expects to earn an adjusted $18.90 to $20.30 per share. The midpoint of that outlook, $19.60, fell short of analysts’ expectations for $19.96, according […]
Amgen (AMGN) stock slumped Monday — as Eli Lilly (LLY) stock hit a record high — after the biotech company said its experimental weight-loss drug appeared durable for up to 150 days. X In one Amgen study, animals received the same dosage three times. At the highest dose, the animals lost an average 8.2% of […]